NAV

COVID-19 convalescent plasma

Identification

Name
COVID-19 convalescent plasma
Accession Number
DB15692
Description

COVID-19 convalescent plasma is plasma collected from patients who have acquired and subsequently recovered from COVID-19 and which contains antibodies against the causative agent SARS-CoV-2.2 This investigational COVID-19 treatment is currently available through three main pathways: use in registered clinical trials, use through the expanded access COVID-19 protocol (21 CFR 312.305), and use for single patients through an emergency IND (eIND; 21 CFR 312.310).2

Although there are no formal clinical trial results for the safety or efficacy of COVID-19 convalescent plasma, early results from 5000 patients under the FDA expanded access program suggest that convalescent plasma transfusion in COVID-19 patients is safe.1

Type
Biotech
Groups
Investigational
Synonyms
  • Convalescent plasma (COVID-19)

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
YM6LN8TU2V
CAS number
Not Available

References

General References
  1. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, Carter RE, Klompas AM, Wiggins CC, Shepherd JR, Rea RF, Whelan ER, Clayburn AJ, Spiegel MR, Johnson PW, Lesser ER, Baker SE, Larson KF, Ripoll JG, Andersen KJ, Hodge DO, Kunze KL, Buras MR, Vogt MN, Herasevich V, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, van Buskirk CM, Winters JL, Stubbs JR, Paneth NS, Verdun NC, Marks P, Casadevall A: Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest. 2020 Jun 11. pii: 140200. doi: 10.1172/JCI140200. [PubMed:32525844]
  2. FDA recommendations for investigational COVID-19 convalescent plasma [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Enrolling by InvitationTreatmentCoronavirus Disease 2019 (COVID‑19)1
3Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)2
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID19 Pneumonia1
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID / COVID - 191
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID / COVID - 19 / Infections, Coronavirus / Viral Pneumonia1
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID / COVID - 19 / Infectious Diseases1
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus / RNA Virus Infections / Virus Diseases1
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / SARS-CoV-2 Infection (COVID-19)1
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Severe Acute Respiratory Syndrome Coronavirus 21

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created on June 16, 2020 14:31 / Updated on June 17, 2020 16:27

134